Scott T. Tagawa, MD, MS

Articles by Scott T. Tagawa, MD, MS

Prostate Cancer Management: Future Directions in Care

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Clinical Pearls and Practical Advice

ByAndrew J. Armstrong, MD,A. Oliver Sartor, MD,Scott T. Tagawa, MD, MS

May 19th 2022

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.

Addressing Bone and Visceral Metastases in Metastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 18th 2022

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

Emerging Targeted Therapies in mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

May 12th 2022

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Defining Unmet Needs in the Management of mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

May 12th 2022

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Selecting Among Novel Imaging Options in Metastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Utility of Imaging as a Biomarker

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 11th 2022

Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.

Ongoing PSMA-Targeted Radioligand Trials in mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

May 5th 2022

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Metastatic CRPC: Considerations for Radiotherapy

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

May 5th 2022

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

DNA Alterations and Selection of PARP Inhibitors in mCRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 4th 2022

Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

Overview of Therapy for mCRPC: PARP Inhibitors

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 4th 2022

A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.

Potential Role of Lu-PSMA-617 in mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

April 28th 2022

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

VISION Trial: Lu-PSMA-617 in mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

April 28th 2022

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Interpreting Data From the ARASENS Trial in Metastatic HSPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 27th 2022

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 27th 2022

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.

Role of Radium-223 in Treating mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

April 21st 2022

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Patient Factors in Selecting Therapy for mCRPC

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

April 21st 2022

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Role of Micronized Abiraterone in Metastatic HSPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 20th 2022

Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.

Overview of Treatment for Metastatic HSPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 20th 2022

Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.

Monitoring Strategies in Nonmetastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 13th 2022

A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].

Phenotypic Biomarkers in the Management of Prostate Cancer

ByAndrew J. Armstrong, MD,Scott T. Tagawa, MD, MS,Oliver Sartor, MD

April 6th 2022

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 6th 2022

Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.

Background on Prostate Cancer and Biomarker Testing

ByAndrew J. Armstrong, MD,Oliver Sartor, MD,Scott T. Tagawa, MD, MS

April 6th 2022

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Evolving Treatment Landscape of Nonmetastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MBBS, Stanford Cancer Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 6th 2022

Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.

Future Outlook on the Management of Metastatic Urothelial Cancer

ByArlene O. Siefker-Radtke, MD,Scott T. Tagawa, MD, MS

December 15th 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa consider how the urology field will likely advance with more interest in genomic profiling in metastatic urothelial cancer and novel therapies in the pipeline.